Healthy
Conditions
Keywords
Healthy, Positron Emission Tomography, 11C-MK-3168, JNJ-42165279, Human Brain
Brief summary
The purpose of the study is to measure the uptake, distribution, and clearance of 11C-MK-3168 by Positron Emission Tomography (PET) scan and to model the tissue specific kinetics of 11C-MK-3168 with the appropriate input function in human brain in Part A; to measure blocking of retention of 11C-MK-3168 at the estimated time to maximum plasma concentration after dosing (tmax) following each single oral doses of JNJ-42165279 and model the exposure/enzyme interaction of JNJ-42165279 in Part B; to measure the saturation of enzyme inhibition in the brain at steady state plasma concentrations of JNJ-42165279 (on Day 8) after 7 once-daily doses of JNJ-42165279 by conducting PET studies with 11C-MK-3168 at trough plasma concentrations on Day 2 in Part C.
Detailed description
This is an open-label (both \[participants and investigator\] know what treatment participants will receive) study. This study consists of 3 consecutive parts: A, B, and C. Each part will consist of a screening phase (between 21 to 2 days prior to the study medication), a treatment phase (Part A: 1 day; Part B: 8 days; Part C: 8 days), and the end-of-study/ follow-up visit (within 5 to 7 days after last PET scan). In the treatment phase of the Part A, participants will undergo a baseline PET/computed tomography scan (after administration of 11C-MK-3168 on Day 1); In Part B, participants will undergo a baseline PET scan, followed by 2 post-treatment PET scans after 2 single doses of JNJ-42165279 on Days 1 and 8; in Part C, participants will undergo a baseline PET scan, followed by 2 post-treatment PET scans after 24 hours postdose of JNJ-42165279 on Days 1 and 7. Safety will be evaluated by the assessment of adverse events, vital signs, 12-lead electrocardiogram, clinical laboratory testing, physical examination (including weight and tympanic temperature \[temperature measure in an ear\]), and neurological examination. The total duration of study participation for a participant will be approximately 4 weeks for Part A and approximately 5 weeks for Parts B and C.
Interventions
DRUGJNJ-42165279
Participants will receive oral suspension of JNJ-42165279 in Part B as single dose on Day 1 (100 mg) and on Day 8 (up to 250 mg); in Part C as once daily dose (up to 100 mg) from Day 1 to Day 7.
DRUG11C-MK-3168
Participants will receive 11C-MK-3168 in the target range of 185 to 370 megabecquerel (MBq) intravenously (into a vein) before every positron emission tomography scan in Parts A, B, and C.
Sponsors
Janssen Research & Development, LLC
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Body mass index (BMI) between 18 and 30 kg/m2 inclusive (BMI = weight/height2) * Non-smoker (not smoked for 3 months prior to screening) * Agree to use one of the protocol mentioned barrier methods of birth control
Exclusion criteria
* Exposed to 1 millisievert or more of ionizing radiation in the year before the start of this study * Clinically significant abnormal laboratory values and abnormal physical and neurological examination at screening * Any clinically significant Magnetic Resonance Imaging (MRI) abnormalities at screening, as determined by a neuroradiologist, which are relevant for the study * Allen test (test to assess the arterial blood flow to the hand) indicating abnormal blood supply to the hand * Has implanted or embedded metal objects, or fragments in the head or body that would present a risk during the MRI scanning procedure
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Part C: Dose and Time Dependent Occupancy of FAAH After Repeat Dose of JNJ-42165279 | Upto 5 weeks | Occupancy of FAAH in brain by JNJ-42165279 at steady state will be evaluated by comparing the distribution volume of 11C-MK-3168 at Tmax after single dose JNJ-42165279 and then at trough after dosing for seven days with JNJ-42165279 to the distribution volume prior to treatment. |
| Part A: Compartmental Model of the Volume of Distribution of 11C-MK-3168 in Brain by Positron Emission Tomography (PET) | Day 1 | Uptake, distribution, and clearance of 11C-MK-3168 in the brain and plasma of healthy male participants will be evaluated by PET scan and arterial sampling. |
| Part B: Dose Dependent Occupancy of Fatty Acid Amide Hydrolase (FAAH) After Single Dose of JNJ-42165279 | Up to 5 weeks | Occupancy of the FAAH in brain by JNJ-42165279 will be evaluated by comparing the distribution volume of 11C-MK-3168 after single dose JNJ-42165279 to the distribution volume at baseline. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Correlation Between Fatty Acid Amide Hydrolase (FAAH) Occupancy in Brain With Peripheral FAAH inhibition | Postdose Day 1 and Day 8 | Correlation between peripheral and central FAAH inhibitions in white blood cells by JNJ 42165279 will be measured. |
| Effect of FAAH C385A polymorphism on the distribution volume of 11C-MK-3168 in human brain | Postdose Day 1 and Day 8 | Effect of FAAH C385A polymorphism on the distribution volume of 11C-MK-3168 in human brain will be assessed. |
| Number of participants with adverse events | Up to 5 weeks | Number of participants with adverse events will be reported as an assessment of safety and tolerability of 11C-MK-3168 and JNJ-42165279. |
Countries
Belgium
Outcome results
None listed